Clinical Features and the Diagnostic Value of Component Allergen-Specific IgE in Hymenoptera Venom Allergy

Yoo Seob Shin, Jing Nan Liu, Gyu-Young Hur, Eui-Kyang Hwang, Young Hee Nam, Hyun Jung Jin, Sang Min Lee, Young-Min Ye, Dong-Ho Nahm, Hae-Sim Park

1Department of Allergy and Clinical Immunology, Ajou University School of Medicine, Suwon, Korea
2Department of Internal Medicine, Korea University College of Medicine, Seoul, Korea
3Department of Medicine, Gacheon University of Medicine and Science, Incheon, Korea

Purpose: Although patient history is vital for the diagnosis of hymenoptera venom allergy, specific IgE detection is also important to identify the culprit insect and monitor the effect of immunotherapy. We evaluated the diagnostic value of serum-specific IgE detection of hymenoptera venom component allergens and documented changes in allergen-specific IgE after immunotherapy. Methods: Fifty-six hymenoptera venom allergy patients receiving venom immunotherapy were recruited from Ajou University Hospital, Korea. The clinical manifestations of the patients were noted, and serum-specific IgE detection was performed, using conventional venom extracts as well as component allergens. Data were analyzed retrospectively. Results: A total of 35 (62.5%) patients were male, and 33 (73.3%) patients were atopic. The mean patient age was 44.9 ± 13.8 years. Localized reactions occurred in 23.2% of patients, and systemic reactions occurred in 76.8%. The most common clinical manifestations included skin involvement, such as urticaria and angioedema, and respiratory involvement. Yellow jackets were the most frequent culprit insect, followed by yellow hornets, white-faced hornets, honeybees, and paper wasps, as determined at the time of diagnosis. Double sensitization to both Apidae and Vespidae species was detected in 70.9% of patients. The positive predictive values (PPV) of rVes v 5-specific and rPol d 5-specific IgE detection were 85.7% and 87.5%, respectively, which correlated well with conventional venom extract-specific IgE detection (r = 0.762 and r = 0.757, respectively). In contrast, the PPV of rApi m 1-specific IgE detection at the time of diagnosis was 34.8%. Three years of venom immunotherapy resulted in decreased venom-specific IgE, particularly IgE specific for Vespidae venom components. Conclusions: Stings by yellow jackets and male sex may be risk factors for hymenoptera venom allergy in Korea. Vespidae component-specific IgE, but not Apidae component-specific IgE, had diagnostic and monitoring value in hymenoptera venom allergy comparable to that of conventional hymenoptera venom extract-specific IgE. Key Words: Hymenoptera venom; component-resolved diagnosis; immunotherapy

INTRODUCTION

Stinging insects belong to the order Hymenoptera. The Hymenoptera families most relevant to allergies are the Apidae, Vespidae, and Formicidae. The Apidae and Vespidae are responsible for hymenoptera venom allergy, and stings by these bees and wasps can lead to local or systemic reactions, including anaphylaxis. Systemic allergic reactions to hymenoptera stings have been reported in ≤ 3% of adults, and nearly 1% of children have a medical history of severe hymenoptera sting reactions. A patient’s medical history is the primary and most important tool used to diagnose hymenoptera venom allergy. However, this information has limited value for identifying the culprit species. An exact diagnosis is needed for the development of an effective strategy for immunotherapy, and thus, other methods, such as skin prick tests and serum-specific IgE detection, are also used. Serological measurement of venom-specific IgE antibodies can confirm sensitization in hymenoptera venom allergy patients. Although conventional venom extracts are used to measure serum-specific IgE in commercially available im-
munoassay systems, venom is a complex of many substances. For example, the major component allergens of honeybee venom include phospholipase A2 and hyaluronidase, and those of Vespidae include phospholipase A1, antigen 5, and hyaluronidase. Despite the component allergen differences between honeybee and Vespidae venoms, >50% of hymenoptera venom allergy patients react to both venoms in serologic tests.

Component-resolved diagnosis (CRD) was introduced after the development of microarrays that test for 94 purified allergens, including hymenoptera venoms. CRD uses defined allergens as antigens, instead of whole allergen extracts, which are mixtures of both allergenic and non-allergenic components. Some studies have demonstrated the highly sensitive and specific diagnostic value of component allergen-specific IgE detection for food, cat, birch, and grass pollen allergies. A recent study using recombinant component allergens to investigate the cross-reactivity of IgE antibodies for different hymenoptera venoms found that cross-reacting carbohydrate determinants (CCDs) were the main cause of double sensitization.

In this study, we compared the diagnostic value of component allergen-specific IgE to that of conventional venom extract-specific IgE and evaluated antibody cross-reactivity for Apidae and Vespidae species allergen components.

MATERIALS AND METHODS

Patients
Fifty-six patients who had been diagnosed with hymenoptera venom allergy and who had received venom immunotherapy at Ajou University Hospital in Suwon, Korea, between April 1998 and April 2011 were enrolled in the study. The diagnosis of hymenoptera venom allergy and the choice of venom allergen (Hollister-Stier, Spokane, WA, USA) used for allergen immunotherapy were made based on patient history and the levels of serum-specific IgE to major venoms measured at the time of diagnosis.

Clinical manifestations
The demographic characteristics of the enrolled patients were reviewed, and information regarding age, gender, atopy status (based on skin prick tests or in vitro allergen-specific IgE results), acupuncture history using honeybee extract, cross-reactivity with fire ant (Solenopsis invicta) allergen, and the severity of clinical manifestations were recorded retrospectively. We identified anaphylaxis patients following National Institute of Allergy and Infectious Disease (NIAID)/Food Allergy and Anaphylaxis Network (FAAN) criteria and classified these patients as severe or moderate based on the grading system for generalized hypersensitivity reactions.

Measurement of serum-specific IgE
Serum levels of IgE specific for major hymenoptera venom extracts (i.e., honeybee, yellow jacket, yellow hornet, white-faced hornet, and paper wasp) and three hymenoptera venom component allergens (recombinant phospholipase A2 from honeybee [rApi m 1], recombinant antigen 5 from yellow jacket [rVes v 5], and recombinant antigen 5 from paper wasp [rPol d 5]) were measured using an ImmunoCAP system (Pharmacia, Uppsala, Sweden). Patient blood samples were obtained at the time of diagnosis and 3 years after immunotherapy. Allergen-specific IgE levels >0.35 kUA/L were considered positive, and individuals with positive IgE levels to any two of the major bee venoms were considered to have double sensitization.

Statistical analysis
Clinical features were reported by descriptive analysis. Correlations between results for conventional venom extracts and component allergens were calculated by Pearson’s correlation test. Wilcoxon’s rank test was used for nonparametric analysis of changes in serum allergen-specific IgE after hymenoptera venom allergen immunotherapy. Differences were considered statistically significant at P<0.05.

RESULTS

Clinical characteristics of study subjects
The clinical characteristics of the study subjects are summarized in Table 1. Male patients (62.5%) were predominant, consistent with other studies, and the mean patient age was 44.9 ± 13.8 years (range, 11-73 years). Based on skin prick tests or serum levels of IgE specific to common aeroallergens, 73.3% of the study population had atopic tendencies. Of note, 10.7% of the patients developed allergies due to honeybee extract acupuncture therapy, which is widely used in oriental medicine to relieve pain.

As our study design selected for patients who had received venom allergen immunotherapy, few patients (17.3%) had low

| Characteristic          | No. (%) |
|-------------------------|---------|
| Gender                  |         |
| Male                    | 35 (62.5) |
| Female                  | 21 (37.5) |
| Age* (yr)               | 44.9 ± 13.8 |
| Age range (yr)          | 11-73    |
| Atopy                   | 33 (73.3) |
| Honeybee acupuncture    | 6 (10.7)  |
| Cross-reactivity with fire ant | 12 (48.0) |
| Local reaction          | 13 (23.2) |
| Systemic reaction       | 43 (76.8) |
| -Severe manifestation   | 21 (37.5) |
| -Moderate manifestation | 22 (39.3) |

Table 1. Clinical characteristics and symptom severity of the study population

*Value is presented as mean ± SD.
bees, including recombinant phospholipase A2 from honeybee (Api m 1), recombinant antigen 5 from yellow jacket (Ves v 5), and recombinant antigen 5 from paper wasp (Pol d 5). The positive predictive values (PPVs) of Ves v 5-specific and Pol d 5-specific IgE detection were 85.7% and 87.5%, respectively.

These were positively correlated with conventional venom extract-specific IgE detection ($r = 0.762$ and $r = 0.757$, respectively). In contrast, the PPV of Api m 1 was 34.8% at the time of diagnosis (Fig. 1). Next, we analyzed the status of combined sensitization using component allergens at diagnosis. The combined sensitization within the Vespidae family (Ves v 5 and Pol d 5) was 80%, and there was only 27.3% cross-reactivity between the Apidae and Vespidae families (Api m 1 and Ves v 5, or Api m 1 and Pol d 5).

**Serum-specific IgE levels with venom immunotherapy**

After immunotherapy for 3 years, we observed the change in serum-specific IgE to venom allergens and three components of venom allergen. Specific IgE levels to Vespidae tended to decline compared to those collected before allergen immunotherapy; however, those to Apidae did not change ($P = 0.18$). Among the specific IgE to Vespidae, Ves v 5 and Pol d 5 significantly decreased after 3 years of immunotherapy ($P = 0.046$ and $P = 0.028$, respectively) compared to whole yellow jacket and paper wasp venom extracts ($P = 0.075$ and $P = 0.116$, respectively). Together, these results indicate that for detecting changes in antibody levels in response to allergen immunotherapy, the measurement of IgE specific for Ves v 5 or Pol d 5 is as sensitive as the measurement of IgE specific for conventional Vespidae venom extract (Fig. 2).

**DISCUSSION**

The worldwide incidence of systemic reactions to Hymenoptera is estimated to be about 0.8%-5%,$^2$ and the prevalence of
serum IgE specific for Hymenoptera is even higher. Hymenoptera stings are one of the most common causes of anaphylaxis and result in more than 40 deaths per year in the United States. Venom immunotherapy is the primary treatment for preventing systemic allergic reactions, and its reported success rate is >95%, although this number is biased because of the careful selection of patients and immunotherapy regimens. Hymenoptera venom provocation tests are definitive diagnostic tools, but are often impractical owing to the risk for inducing dangerous symptoms. Thus, clinicians rely on patient history, skin prick tests, and venom-specific IgE detection to determine which allergens to use for immunotherapy.

Many Hymenoptera allergy patients also have IgE specific for other venoms, due to antibody cross-reactivity with homologous peptide sequences in different protein allergens, or to CCDs, which are present in the majority of Hymenoptera venom allergens. Cross-reactive double positivity presents significant challenges in choosing venoms to be used for immunotherapy. After the introduction of the ImmunoCAP system, a highly sensitive test for allergy diagnosis, the reported prevalence of double positivity increased, presumably because of its better detection. Similarly, an increased incidence of food allergies in pollen allergy patients was also reported.

To more definitively identify clinically relevant allergenic components, purified allergens and individual peptides have been developed for use in CRD. CRD has excellent diagnostic and monitoring value for allergies to cats, birch, and grass pollens. So far, however, the reported values of CRD are comparable to those of whole venom extracts. In contrast, the PPVs of honeybee allergens were very low at diagnosis, consistent with previous results showing that CRD using honeybee allergens had a markedly lower diagnostic value compared to basophil activation tests and Western blot analysis, indicating minimal sensitivity to rApi m 1. These results suggest that determining the sensitivity to rApi m 1 alone is not sufficient for accurate diagnosis of honeybee allergies, and CRD for this allergy may require testing for additional component allergens. Other honeybee component allergens have been identified, specifically hyaluronidase (Api m 2) and acid phosphatase (Api m 3), but their clinical relevance is unknown. We determined that Api m 1 was not sensitive enough for proper diagnosis of honeybee allergy, and additional component allergens may be needed for better diagnosis. In the case of birch pollen allergy, the addition of rBet v 1 and rBet v 2 component allergens to CRD in patients increased its sensitivity, compared to ImmunoCAP analysis using whole allergen extract. The lack of commercially available component allergens, especially from the Apidae family, is a major limiting factor for the use of CRD.

Immunotherapy with venom extracts is well known to induce a gradual decline in allergen-specific IgE, with a concomitant increase in allergen-specific IgG. ImmunoCAP analysis is not always the ideal method to measure changes in conventional venom extract-specific IgE, particularly in patients who are sensitized to more than one Hymenoptera allergen. For example, in our study, only IgE antibodies against the component Vespidae allergens (i.e., rVes v 5 and rPol d 5) significantly declined after immunotherapy. Although our data do not demonstrate the sensitivity of allergen component-specific IgE with regard to clinical outcomes, the data do suggest that measuring allergen component-specific IgE is a highly sensitive tool for monitoring IgE levels after immunotherapy.

The clinical features of allergy in this study were similar to those reported in other studies. Interestingly, nearly 10% of the Hymenoptera venom patients in the present study had allergies caused by acupuncture therapy with honeybee extract, and this number might have been much higher if minor reactions had

**Fig. 2.** Effect of immunotherapy on serum IgE specific for whole hymenoptera venom and serum IgE specific for component allergens. Serum levels of IgE specific for (A) yellow jacket venom, (B) rVes v 5, (C) paper wasp venom, and (D) rPol d 5 were measured in allergy patients (n = 6) before and after 3 years of allergen immunotherapy. Data were analyzed by Wilcoxon’s rank test.

http://e-aair.org
been included. Honeybee acupuncture is a traditional method for pain relief in Oriental medicine, but the prevalence of allergic reactions among patients of this therapy has not been reported previously.

In conclusion, Vespidae component allergen-specific IgE was as good as, if not better than, conventional venom extract-specific IgE for identifying and tracking allergen-specific IgE in Hymenoptera allergy patients.

ACKNOWLEDGMENTS

This study was supported by the Korea Science and Engineering Foundation (KOSEF) grant funded by the Korea government (MEST, 2009-0078646).

REFERENCES

1. Golden DB. Stinging insect allergy. Am Fam Physician 2003;67:2541-6.
2. Position paper: Immunotherapy with hymenoptera venoms. (EAACI) The European Academy of Allergology and Clinical Immunology. Allergy 1993;48:36-46.
3. King TP, Sobotka AK, Kochoumian L, Lichtenstein LM. Allergens of honey bee venom. Arch Biochem Biophys 1976;172:661-71.
4. Light WC, Reisman RE, Ilea VS, Wypych JI, Okazaki T, Arbesman CE. Studies of the antigenicity and allergenicity of phospholipase A2 of bee venom. J Allergy Clin Immunol 1976;58:322-9.
5. Owen MD. Chemical components in the venoms of Ropalidia species. J Insect Sci Int 2009;1:186:1-5.
6. Egner W, Ward C, Brown DL, Ewan PW. The frequency and clinical significance of specific IgE to both wasp (Vespula) and honey-bee (Apis) venoms in the same patient. Clin Exp Allergy 1998;28:26-34.
7. Hiller R, Laffer S, Harwanegg C, Huber M, Schmidt WM, Twardosz A, Barletta B, Becker WM, Blaser K, Breiteneder H, Chapman M, Cramer R, Duchêne M, Ferreira F, Fleig H, Hoffmann-Sommergruber K, King TP, Kleber-Janke T, Kurup VP, Lehrer SB, Lidholm J, Müller U, Pini C, Reese G, Scheiner O, Scheynius A, Shen HD, Spitzauer S, Suck R, Swoboda I, Thomas W, Tinghino R, Van Hage-Hamsten M, Virtanen T, Kraft D, Müller MW, Valenta R. Microarrayed allergen molecules: diagnostic gatekeepers for allergy treatment. FASEB J 2002;16:414-6.
8. Wöhrl S, Vgl K, Zehetmayer S, Hiller R, Jarisch R, Prinz M, Stingl G, Kopp T. The performance of a component-based allergen-microarray in clinical practice. Allergy 2006;61:633-9.
9. Pittner G, Vrtala S, Thomas WR, Weghofer M, Kundl M, Horak E, Kraft D, Valenta R. Component-resolved diagnosis of house-dust mite allergy with purified natural and recombinant mite allergens. Clin Exp Allergy 2004;34:597-603.
10. Müller UR, Johansen N, Petersen AB, Fromberg-Nielsen J, Haebler G. Hymenoptera venom allergy: analysis of double positivity to honey bee and Vespucla venom by estimation of IgE antibodies to species-specific major allergens Api m 1 and Ves v 5. Allergy 2009;64:543-8.
11. Sampson HA, Muñoz-Furlong A, Campbell RL, Adkinson NF Jr, Bock SA, Branum A, Brown SG, Camargo CA Jr, Cydulka R, Galli SJ, Gidudu J, Gruchalla RS, Harlor AD Jr, Hepner DL, Lewis LM, Lieberman PL, Metcalfe DD, O’Connor R, Muraro A, Rudman A, Schmitt C, Scherrer D, Simons FE, Thomas S, Wood JP, Decker WW. Second symposium on the definition and management of anaphylaxis: summary report—second National Institute of Allergy and Infectious Disease/Food Allergy and Anaphylaxis Network symposium. Ann Emerg Med 2006;47:573-80.
12. Brown SG. Clinical features and severity grading of anaphylaxis. J Allergy Clin Immunol 2004;114:371-6.
13. Björnsson E, Janson C, Pulasckie P, Normann F, Sjöberg O. Venom allergy in adult Swedes: a population study. Allergy 1995;50:800-5.
14. Golden DB, Marsh DG, Kagey-Sobotka A, Freidhoff L, Szklo M, Valentine MD, Lichtenstein LM. Epidemiology of insect venom sensitivity. JAMA 1989;262:240-4.
15. Shen Y, Li L, Grant J, Ruhio A, Zhao Z, Zhang X, Zhou L, Fowler D. Anaphylactic deaths in Maryland (United States) and Shanghai (China): a review of forensic autopsy cases from 2004 to 2006. Forensic Sci Int 2009;186:1-5.
16. Bonifazi E, Jutel M, Bilde BM, Birnbaum J, Muller U; EAACI Interest Group on Insect Venom Hypersensitivity. Prevention and treatment of hymenoptera venom allergy: guidelines for clinical practice. Allergy 2005;60:1459-70.
17. Akkoc T, Akdis M, Akdis CA. Update in the mechanisms of allergen-specific immunotherapy. Allergy Asthma Immunol Res 2011;3:11-20.
18. Hemmer W, Focke M, Kolarich D, Wilson IB, Altmann F, Wöhrl S, Götz M, Jarisch R. Antibody binding to venom carbohydrates is a frequent cause for double positivity to honeybee and yellow jacket venom in patients with stinging-insect allergy. J Allergy Clin Immunol 2001;108:1045-52.
19. Blank S, Seismann H, Bockisch B, Braren I, CIFuentes L, McIntyre M, Rühl D, Ring J, Brededor R, Ollert MW, Grunwald T, Spillner E. Identification, recombinant expression, and characterization of the 100 kDa high molecular weight Hymenoptera venom allergens Api m 5 and Ves v 3. J Immunol 2010;184:5403-13.
20. Jin C, Focke M, Léonard D, Jarisch R, Altmann F, Hemmer W. Reassessing the role of hyaluronidase in yellow jacket venom allergy. J Allergy Clin Immunol 2010;125:184-90.e1.
21. Hemmer W, Focke M, Kolarich D, Dalik J, Götz M, Jarisch R. Identification by immunoblot of venom glycoproteins displaying immunoglobulin E-binding N-glycans as cross-reactive allergens in honeybee and yellow jacket venom. Clin Exp Allergy 2004;34:460-9.
22. Kochuyt AM, Van Hoeyveld EM, Stevens EA. Prevalence and clinical relevance of specific immunoglobulin E to pollen caused by stinging-induced specific immunoglobulin E to cross-reacting carbohydrate determinants in Hymenoptera venom. Clin Exp Allergy 2005;35:441-7.
23. Bircher AJ, Van Melle G, Haller E, Curty B, Frei PC. IgE to food allergens are highly prevalent in patients allergic to pollens, with and without symptoms of food allergy. Clin Exp Allergy 1994;24:367-74.
24. Lin J, Bardina L, Shreffler WG, Andreae DA, Ge Y, Wang J, Bruni FM, Fu Z, Han Y, Sampson HA. Development of a novel peptide microarray for large-scale epitope mapping of food allergens. J Allergy Clin Immunol 2009;124:315-22, 322.e1-3.
25. Sturm GJ, Jin C, Kranzelbinder B, Hemmer W, Sturm EM, Griesbacher A, Heinemann A, Vollmann J, Altmann F, Cralishheim K, Focke M, Aberer W. Inconsistent results of diagnostic tools hamper the differentiation between bee and vespid venom allergy. PLoS One 2011;6:e20842.
erro J, Bonnet-Moreno C. Epidemiology of allergic reactions in beekeepers: a lower prevalence in subjects with more than 5 years exposure. Allergol Immunopathol (Madr) 1995;23:127-32.
27. Annila IT, Karjalainen ES, Mörsy P, Kuusisto PA. Clinical symptoms and immunologic reactivity to bee and wasp stings in beekeepers. Allergy 1995;50:568-74.
28. Hur GY, Kim JE, Ye YM, Suh CH, Nahm DH, Park HS. Clinical features of bee venom allergy. Korean J Asthma Allergy Clin Immunol 2006;26:145-50.